A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
Completed · Phase 3 · NCT03882970
Conditions: Type 2 Diabetes Mellitus
At a glance
- Research payments reported, 2025
- $473
- U.S. investigators named
- 1
- Sites paid
- 1
- Planned or actual enrollment
- 1,444
About the trial
- Sponsor
- Eli Lilly and Company
- Tested
- Tirzepatide (drug), Insulin Degludec (drug)
- Dates
- Started 2019-04-01; completion 2021-01-04
- Results posted
- Yes
The purpose of this study is to compare the effect of the study drug tirzepatide to insulin degludec on blood sugar levels in participants with type 2 diabetes. The study will last about 67 weeks and may include up to 22 visits.
From ClinicalTrials.gov, last updated 2022-01-19. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Eli Lilly and Company reported $473 in research payments for this study in 2025 (1 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Andrew J Lewin Med DBA National Rsrch Institute $473
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.